Bio-Rad Laboratories Inc (STU:BUWA)
€ 344.3 4.8 (1.41%) Market Cap: 9.37 Bil Enterprise Value: 9.16 Bil PE Ratio: 0 PB Ratio: 1.39 GF Score: 75/100

Bio Rad Laboratories Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 05:40PM GMT
Release Date Price: €260.5 (-0.02%)
Michael Leonidovich Ryskin
BofA Merrill Lynch, Research Division - Associate

So we're ready to get started. So my name is Mike Ryskin. I'm on the Life Science Tools and Diagnostics Team here at Bank of America Merrill Lynch. Thank you for joining us for the conference. I'm here on behalf of the senior analyst on the team, Derik de Bruin. Unfortunately, he couldn't make it today. He had surgery recently; he's unable to travel right now, but he's certainly here in spirit. He would be if he could, and he's following on the webcast where available. On his behalf I'd be remiss if I didn't ask for an [aye-aye] vote. I know it's everyone's favorite time of the season, but he's pretty emphatic that we get the ask out. So the entire tools team and all of Bank of America appreciates your support on that. And so this part of the session is Bio-Rad. We're joined by Norman Schwartz and Ilan Daskal from the company. Thank you for joining us, gentlemen.

Just to start, maybe a high level discussion. If you look at Bio Rad over the last couple years, there's certainly been a lot of change in the company,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot